Nanosized Tamoxifen-Porphyrin-Glucose [TPG] Conjugate: Novel Selective Anti-breast-cancer Agent, Synthesis and In Vitro Evaluations

Ali      Jabbari Arabzadeh; Mehdi      Shafiee Ardestani; Abolfazl      Dashtbani-Roozbehani; Seyed      Ali Delbaz; Mohammad      Shafiee Alavidjeh; Hadi      Fathi Moghaddam; Alireza      Azizi Saraji; Mahmood      Alaei-Beirami; Soheila      Hekmat; Massoud      Amanlou; Mehdi      Hajmohammadi; Seyed      Mehdi Sadat; Seyed      Esmaeil Sadat Ebrahimi; Masoud      Ghorbani; Mohammad      Reza Aghasadeghi; Seyed      Davar Siadat; Zahra      Heidari

Abstract

Tumor and especially breast cancer is among the most common causes of death worldwide. Finding novel nanosized therapeutic compounds have important role to decrease the chance of death and increase the survival. Cancer cells are highly attractive to glucose [with a nanosize bimolecular structure 1nm] as an energy source more than normal cell and nanosized therapeutics due to possessing different pharmacokinetic and pharmacodynamic have advantageous over classical dosage forms in cancer therapy. The aim of the study was to synthesize Glucosamin-Porphyrin-Tamoxifen [TPG] nanosized complex as a novel selective biocompatible anti breast cancer agent. After the synthesis procedure, this complex was purified and then tested In Vitro on breast cancer cells [MCF-7] in the absence or presence of the red light and found totally successful. The results showed a good anti breast cancer activity mediated by the activation of TNF-α and necrosis/apoptosis pathways for the nanosized complex with no alteration effects on blood PT/APTT and glucose or hexokinase levels/ activity. TPG nanoconjugate seems to be very good opponents to current anti breast cancer drugs and needs to be further investigated in near future.

Keywords: Breast cancer, tamoxifen, porphyrin, glucosamine, N-demethylation, human mammary cancer cell line [MCF- 7]

« Previous Next »